American Century Companies Inc. Boosts Position in Twist Bioscience Co. (NASDAQ:TWST)

American Century Companies Inc. increased its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 63.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 756,352 shares of the company's stock after acquiring an additional 293,751 shares during the quarter. American Century Companies Inc. owned about 1.27% of Twist Bioscience worth $35,148,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Magnetar Financial LLC bought a new position in shares of Twist Bioscience in the fourth quarter valued at about $337,000. Teacher Retirement System of Texas grew its stake in Twist Bioscience by 18.9% in the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock valued at $807,000 after buying an additional 2,755 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after acquiring an additional 532,040 shares during the period. Cibc World Markets Corp acquired a new stake in Twist Bioscience during the fourth quarter worth approximately $253,000. Finally, Swiss National Bank boosted its holdings in shares of Twist Bioscience by 1.1% during the fourth quarter. Swiss National Bank now owns 115,200 shares of the company's stock worth $5,353,000 after acquiring an additional 1,200 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently commented on TWST shares. Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday, February 4th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Finally, Barclays set a $58.00 price objective on Twist Bioscience and gave the company an "overweight" rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.

Remove Ads

Twist Bioscience Stock Down 1.9 %

NASDAQ TWST traded down $0.73 on Wednesday, hitting $38.21. 1,546,412 shares of the company were exchanged, compared to its average volume of 944,777. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The stock has a fifty day moving average of $44.47 and a 200-day moving average of $45.23. The company has a market cap of $2.28 billion, a PE ratio of -11.30 and a beta of 2.15. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the previous year, the business posted ($0.75) EPS. Twist Bioscience's quarterly revenue was up 24.1% on a year-over-year basis. As a group, analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at approximately $4,762,752.96. This represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,799 shares of company stock valued at $1,593,944 over the last 90 days. Insiders own 3.01% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.